PepGen Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- James McArthur
- Full Time Employees
- 57
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 321 Harrison Avenue Boston MA United States of America 02118
- IPO Date
- May 6, 2022
- CIK
- 0001835597
- Website
- pepgen.com
- Similar Companies
- Business
- PepGen Inc. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company founded in 2018 and headquartered at 321 Harrison Avenue, Boston, Massachusetts, develops next-generation oligonucleotide therapeutics leveraging its proprietary Enhanced Delivery Oligonucleotide (EDO) platform to address severe neuromuscular and neurological diseases, including myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). The company's lead candidates include PGN-EDODM1, an EDO peptide-conjugated phosphorodiamidate morpholino oligomer (PMO) in Phase 2 trials (FREEDOM2-DM1, recruiting; FREEDOM-DM1, enrollment completed) targeting splicing correction in DM1 patients aged 16-60; PGN-EDO51 in Phase 2 for exon 51-skipping amenable DMD patients; and PGN-EDO53 in preclinical development for DMD, with the EDO technology engineered for improved tissue penetration, cellular uptake, and nuclear delivery across muscle types and the central nervous system. PepGen operates primarily in the United States, focusing on rare genetic disorders with high unmet needs through its pipeline of disease-modifying therapies; it also supports custom oligonucleotide synthesis, preclinical development services including PK/PD studies and toxicology, and expertise in peptide-drug conjugates for blood-brain barrier crossing. In September 2025, PepGen closed a $115 million underwritten public offering of common stock priced at $3.20 per share, including the full exercise of underwriters' option for additional shares led by Leerink Partners and Stifel, with net proceeds funding ongoing clinical trials such as FREEDOM-DM1 and FREEDOM2-DM1, research expansion, working capital, and general corporate purposes; the company continues to advance discovery programs in additional neuromuscular and neurological indications while maintaining approximately 81 employees and leadership under President and CEO James McArthur.
Company News
ADAR1 Capital Management LLC Acquires New Shares in PepGen, Inc. $PEPG
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG